Literature DB >> 34561553

Metabolic reprograming of MDSCs within tumor microenvironment and targeting for cancer immunotherapy.

Qing Li1, Ming Xiang2.   

Abstract

A number of emerging studies in field of immune metabolism have indicated that cellular metabolic reprograming serves as a major administrator in maintaining the viability and functions of both tumor cells and immune cells. As one of the most important immunosuppressive cells in tumor stroma, myeloid-derived suppressor cells (MDSCs) dynamically orchestrate their metabolic pathways in response to the complicated tumor microenvironment (TME), a process that consequently limits the therapeutic effectiveness of anti-cancer treatment modalities. In this context, the metabolic vulnerabilities of MDSCs could be exploited as a novel immune metabolic checkpoint upon which to intervene for promoting the efficacy of immunotherapy. Here, we have discussed about recent studies highlighting the important roles of the metabolic reprograming and the core molecular pathways involved in tumor-infiltrating MDSCs. In addition, we have also summarized the state-of-the-art strategies that are currently being employed to target MDSC metabolism and improve the efficacy of antineoplastic immunotherapy.
© 2021. The Author(s), under exclusive licence to CPS and SIMM.

Entities:  

Keywords:  cancer immunotherapy; metabolic intervention; metabolic reprograming; myeloid-derived suppressor cells; tumor microenvironment

Mesh:

Year:  2021        PMID: 34561553      PMCID: PMC9160034          DOI: 10.1038/s41401-021-00776-4

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   7.169


  139 in total

Review 1.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

Review 2.  AMPK--sensing energy while talking to other signaling pathways.

Authors:  D Grahame Hardie
Journal:  Cell Metab       Date:  2014-10-30       Impact factor: 27.287

3.  Myeloid-specific expression of human lysosomal acid lipase corrects malformation and malfunction of myeloid-derived suppressor cells in lal-/- mice.

Authors:  Peng Qu; Cong Yan; Janice S Blum; Reuben Kapur; Hong Du
Journal:  J Immunol       Date:  2011-09-07       Impact factor: 5.422

4.  Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells.

Authors:  Mikkel G Terp; Kristina A Olesen; Eva C Arnspang; Rikke R Lund; B Christoffer Lagerholm; Henrik J Ditzel; Rikke Leth-Larsen
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

5.  Lactate-Modulated Immunosuppression of Myeloid-Derived Suppressor Cells Contributes to the Radioresistance of Pancreatic Cancer.

Authors:  Xuguang Yang; Yun Lu; Junjie Hang; Junfeng Zhang; Tiening Zhang; Yanmiao Huo; Jun Liu; Songtao Lai; Dawei Luo; Liwei Wang; Rong Hua; Yuli Lin
Journal:  Cancer Immunol Res       Date:  2020-09-11       Impact factor: 11.151

Review 6.  The Emerging Hallmarks of Cancer Metabolism.

Authors:  Natalya N Pavlova; Craig B Thompson
Journal:  Cell Metab       Date:  2016-01-12       Impact factor: 27.287

7.  Oleate but not stearate induces the regulatory phenotype of myeloid suppressor cells.

Authors:  Hao Wu; Carl Weidinger; Franziska Schmidt; Jacqueline Keye; Marie Friedrich; Cansu Yerinde; Gerald Willimsky; Zhihai Qin; Britta Siegmund; Rainer Glauben
Journal:  Sci Rep       Date:  2017-08-08       Impact factor: 4.379

8.  Fatty acid transport protein 2 reprograms neutrophils in cancer.

Authors:  Filippo Veglia; Vladimir A Tyurin; Maria Blasi; Alessandra De Leo; Andrew V Kossenkov; Laxminarasimha Donthireddy; Tsun Ki Jerrick To; Zach Schug; Subhasree Basu; Fang Wang; Emanuela Ricciotti; Concetta DiRusso; Maureen E Murphy; Robert H Vonderheide; Paul M Lieberman; Charles Mulligan; Brian Nam; Neil Hockstein; Gregory Masters; Michael Guarino; Cindy Lin; Yulia Nefedova; Paul Black; Valerian E Kagan; Dmitry I Gabrilovich
Journal:  Nature       Date:  2019-04-17       Impact factor: 49.962

9.  MCT4 promotes cell proliferation and invasion of castration-resistant prostate cancer PC-3 cell line.

Authors:  Qing Sun; Liang-Liang Hu; Qiang Fu
Journal:  EXCLI J       Date:  2019-03-21       Impact factor: 4.068

Review 10.  Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.

Authors:  Andrew M K Law; Fatima Valdes-Mora; David Gallego-Ortega
Journal:  Cells       Date:  2020-02-27       Impact factor: 6.600

View more
  1 in total

Review 1.  Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.

Authors:  Dong-Rui Wang; Xian-Lin Wu; Ying-Li Sun
Journal:  Signal Transduct Target Ther       Date:  2022-09-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.